Novel CDK9 inhibitor oroxylin A promotes wild-type P53 stability and prevents hepatocellular carcinoma progression by disrupting both MDM2 and SIRT1 signaling
Jingyue Yao(China Pharmaceutical University), Libin Wei(State Key Laboratory of Natural Medicine)
Cited by 51
Related Papers
Oroxylin A suppresses the development and growth of colorectal cancer through reprogram of HIF1α-modulated fatty acid metabolism
|Cell Death and Disease|2017|87
RETRACTED ARTICLE: Oroxylin A activates PKM1/HNF4 alpha to induce hepatoma differentiation and block cancer progression
|Cell Death and Disease|2017|70